Getinge B analyst views stay cautious, shares follow healthcare peers

Analyst sentiment on Getinge B remains mixed, with the Swedish medtech group trading broadly in line with European healthcare peers as investors weigh earnings forecasts and margins.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 16:04.

Getinge AB (SE0000202624) sits in focus today as investors look at the analyst consensus for the Swedish medtech group ahead of the next earnings season. The Stockholm-listed healthcare supplier trades in the European sector context, with sentiment shaped by earnings expectations and margin trends from recent quarters.

How analysts rate Getinge

Getinge AB is followed by a relatively small group of international houses compared with large-cap peers such as Siemens Healthineers and Fresenius Medical Care, but the available data shows a mixed stance on the stock. On MarketScreener, the consensus rating clusters between Hold and Buy, with only a minority of analysts on the Sell side. The average price target in that sample points to modest upside versus the latest Stockholm close, reflecting cautious optimism rather than a strong conviction call.

According to consensus compilations on platforms such as Refinitiv and Bloomberg, Getinge’s earnings forecasts for the current year imply mid-single-digit organic sales growth and a gradual margin recovery after previous operational setbacks. The group’s adjusted EBITA margin is projected by several analysts to improve by around 50 to 100 basis points year on year, provided cost savings and product mix effects materialize. This leaves Getinge trading at a discount to faster-growing medtech names, but broadly aligned with mature peers in the European healthcare equipment space.

Consensus figures and peer context

In the wider sector, companies such as Gerresheimer and Genuit have recently reported or guided for solid demand in medical packaging and infrastructure-related products, which helps frame Getinge’s position among European industrial healthcare suppliers. Sector commentary from Reuters highlights that healthcare equities in Europe trade at a moderate premium to the broader STOXX Europe 600 index, backed by defensive earnings and stable cash flows. Within that environment, Getinge’s valuation metrics sit in the mid-range, neither marked as especially expensive nor clearly distressed.

Analysts at Nordic brokerages, including SEB and Handelsbanken, emphasize Getinge’s exposure to hospital capital expenditure and long-term service contracts, factors that typically provide earnings visibility but can also delay short-term growth when procurement cycles slow. The consensus for revenue growth in the next two years remains relatively steady, supported by intensive care, operating room and sterilization solutions demand as hospitals refresh equipment or expand capacity. For investors tracking the stock on Nasdaq Stockholm, this mix of stable demand and moderate margin improvement is reflected in neutral-to-positive recommendations rather than aggressive upgrades.

How Getinge makes its money

Getinge generates most of its revenue from advanced medical technology used in hospitals and healthcare facilities, including intensive care units, operating rooms and sterilization departments. Key product areas include ventilators, anesthesia systems, surgical tables, heart-lung machines, and infection control equipment such as washers and sterilizers. The group also builds a recurring revenue base through service, maintenance and software solutions supporting workflow and quality assurance in critical care environments.

Where the shares trade today

Getinge AB shares (SE0000202624) trade on Nasdaq Stockholm in Swedish kronor. As of 2026-06-23, 15:45, the shares last changed hands at 237.50 SEK on the Stockholm exchange, according to Nasdaq data. This price levels the company at a market capitalization of roughly 61 billion SEK, placing it firmly in the mid-to-large-cap bracket of the Swedish healthcare sector.

Key data on the Getinge AB shares

• Company: Getinge AB
• ISIN: SE0000202624
• WKN: 890908
• Ticker: GETI-B
• Trading venue: Nasdaq Stockholm
• Price (as of 2026-06-23, 15:45): 237.50 SEK
• Market cap: 61,000,000,000 SEK (as of 2026-06-23)
• Sector / industry: Health Care Equipment & Supplies
• Index membership: OMX Stockholm Benchmark
• Next earnings date: 2026-07-18

Disclaimer: This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.